Matching articles for "Dolophine"
Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)
The Medical Letter on Drugs and Therapeutics • August 27, 2018; (Issue 1554)
...
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Management of Opioid Withdrawal Symptoms
The Medical Letter on Drugs and Therapeutics • August 27, 2018; (Issue 1554)
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance...
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance treatment.
Withdrawal management without subsequent maintenance
treatment is associated with high rates of
relapse, overdose death, and HIV and/or hepatitis C
virus infection. Several guidelines on management
of opioid withdrawal are available. Maintenance
treatment of opioid use disorder was reviewed in a
previous issue.
Lofexidine (Lucemyra) for Opioid Withdrawal
The Medical Letter on Drugs and Therapeutics • July 16, 2018; (Issue 1551)
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK...
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK since
1992, lofexidine is the first nonopioid to be approved
in the US for management of opioid withdrawal
symptoms. Clonidine (Catapres, and generics), another
central alpha2 receptor agonist, has been used off-label
for this indication for many years.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
...
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is
associated with economic hardship, social isolation,
incarceration, increased rates of...
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is
associated with economic hardship, social isolation,
incarceration, increased rates of blood-borne
infections such as HIV and viral hepatitis, adverse
pregnancy outcomes, and increased mortality.
According to the CDC, there were 33,091 deaths
related to opioid overdose in the US in 2015, more
than in any previous year. Several guidelines on the
management of opioid use disorder have recently
been published.
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2013; (Issue 128)
Pain can be acute or chronic. The two major types of
chronic pain are nociceptive pain and neuropathic
pain. Nociceptive pain can be treated with nonopioid
analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. The two major types of
chronic pain are nociceptive pain and neuropathic
pain. Nociceptive pain can be treated with nonopioid
analgesics or opioids. Neuropathic pain is less responsive
to opioids and is often treated with adjuvant drugs
such as antidepressants and antiepileptics. Combining
different types of analgesics may provide an additive
analgesic effect without increasing adverse effects.
Quetiapine (Seroquel) and QT-Interval Prolongation
The Medical Letter on Drugs and Therapeutics • October 3, 2011; (Issue 1374)
The FDA has required the manufacturer of the secondgeneration
antipsychotic quetiapine (Seroquel) to add a
warning to the labeling saying that use of the drug should
be avoided in combination with other...
The FDA has required the manufacturer of the secondgeneration
antipsychotic quetiapine (Seroquel) to add a
warning to the labeling saying that use of the drug should
be avoided in combination with other drugs that prolong
the electrocardiographic QTc interval (Table 1). The
warning is based only on postmarketing reports of QT-interval
prolongation in patients who overdosed on the
drug, had concomitant illness, or were taking other drugs
known to cause electrolyte imbalances or increase the
QT interval. QT prolongation can lead to torsades de
pointes, a potentially fatal cardiac arrhythmia.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2010; (Issue 92)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Dronedarone (Multaq) for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • October 5, 2009; (Issue 1322)
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but...
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2007; (Issue 56)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Drugs for Tuberculosis
The Medical Letter on Drugs and Therapeutics • December 1, 2004; (Issue 28)
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into...
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • July 1, 2004; (Issue 23)
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of...
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Buprenorphine: An alternative to Methadone
The Medical Letter on Drugs and Therapeutics • February 17, 2003; (Issue 1150)
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only...
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain (Buprenex, and others), it offers an alternative to methadone (Dolophine, and others), which is now often abused (New York Times, February 9, 2003; page 1). As a schedule III narcotic, buprenorphine will be subject to fewer prescribing restrictions than a schedule II drug such as methadone (MJ Kreek and FJ Vocci, J Subst Abuse Treat 2002; 23:93).w1150a
Acute Reactions to Drugs of Abuse
The Medical Letter on Drugs and Therapeutics • March 4, 2002; (Issue 1125)
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and...
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • August 21, 2000; (Issue 1085)
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought...
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • August 14, 1998; (Issue 1033)
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually...
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain.
Acute Reactions to Drugs of Abuse
The Medical Letter on Drugs and Therapeutics • May 10, 1996; (Issue 974)
Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them...
Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them have been reported.
Nalmefene - Long-Acting Injectable Opioid Antagonist
The Medical Letter on Drugs and Therapeutics • October 27, 1995; (Issue 960)
Nalmefene (Revex - Ohmeda), an i methylene analog of naltrexone (Trexan), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid...
Nalmefene (Revex - Ohmeda), an i methylene analog of naltrexone (Trexan), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid drug effects, including respiratory depression, sedation and hypotension and for management of known or suspected opioid overdose in the emergency department. The only other opioid antagonists available in the USA are naloxone (Narcan), which is also injectable but has a short duration of action, and naltrexone, which has a long duration of action but is marketed only for oral use.
Drugs For Tuberculosis
The Medical Letter on Drugs and Therapeutics • August 4, 1995; (Issue 954)
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the...
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).
Naltrexone For Alcohol Dependence
The Medical Letter on Drugs and Therapeutics • July 21, 1995; (Issue 953)
Naltrexone (ReVia -DuPont Pharma), a long-acting oral opioid antagonist previously marketed for treatment of opioid dependence under the trade name Trexan, was recently approved by the US Food and Drug...
Naltrexone (ReVia -DuPont Pharma), a long-acting oral opioid antagonist previously marketed for treatment of opioid dependence under the trade name Trexan, was recently approved by the US Food and Drug Administration (FDA) for treatment of alcohol dependence. The new trade name will now also be used for the old indication.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • March 3, 1995; (Issue 943)
Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to...
Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to placebo is frequent, and patients vary in response to a given agent (KMA Welch, N Engl J Med, 329:1476, 1993; SD Silberstein and RB Lipton, Neurology, 44 suppl 7:S6, Oct 1994).
Butorphanol Nasal Spray for Pain
The Medical Letter on Drugs and Therapeutics • November 12, 1993; (Issue 909)
Butorphanol tartrate, a synthetic opioid agonist-antagonist analgesic previously available for injection, is now being marketed as a nasal spray (Stadol-NS - Mead Johnson). The spray was approved by the US...
Butorphanol tartrate, a synthetic opioid agonist-antagonist analgesic previously available for injection, is now being marketed as a nasal spray (Stadol-NS - Mead Johnson). The spray was approved by the US Food and Drug Administration (FDA) for any type of pain for which an opioid analgesic is appropriate, but the manufacturer is emphasizing use for treatment of migraine headache and postoperative pain. Drugs for pain were reviewed in the Medical Letter, volume 35, page 1, January 8, 1993.
Drugs for Tuberculosis
The Medical Letter on Drugs and Therapeutics • October 29, 1993; (Issue 908)
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the...
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • January 8, 1993; (Issue 887)
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as...
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use, 3rd ed, Skokie, illinois: American pain society, 1992).
Drugs That Cause Pulmonary Toxicity
The Medical Letter on Drugs and Therapeutics • September 21, 1990; (Issue 827)
Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr...
Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et al, Am Rev Respir Dis, 133:321, 488, 1986). Pulmonary effects that are part of a generalized reaction or are indirect effects of drugs - on respiratory muscles, for example, or on the immune system - are not included here.